According to Anika Therapeutics's latest financial reports the company has a price-to-book ratio of 1.85.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 1.56 | 3.21% |
2022-12-31 | 1.51 | -15.98% |
2021-12-31 | 1.80 | -24.3% |
2020-12-31 | 2.38 | -7.45% |
2019-12-31 | 2.57 | 41.99% |
2018-12-31 | 1.81 | -39.6% |
2017-12-31 | 3.00 | -6.66% |
2016-12-31 | 3.21 | 18.09% |
2015-12-31 | 2.72 | -19.9% |
2014-12-31 | 3.40 | -15.49% |
2013-12-31 | 4.02 | 217.72% |
2012-12-31 | 1.27 | -10.2% |
2011-12-31 | 1.41 | 33.48% |
2010-12-31 | 1.06 | -15.31% |
2009-12-31 | 1.25 | 118.85% |
2008-12-31 | 0.5695 | -80.83% |
2007-12-31 | 2.97 | -5.46% |
2006-12-31 | 3.14 | -2.99% |
2005-12-31 | 3.24 | 4.57% |
2004-12-31 | 3.10 | -42.72% |
2003-12-31 | 5.41 | 838.41% |
2002-12-31 | 0.5764 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.30 | 186.25% | ๐บ๐ธ USA |
Medtronic MDT | 2.07 | 11.63% | ๐ฎ๐ช Ireland |
Stryker Corporation SYK | 6.71 | 262.83% | ๐บ๐ธ USA |
STAAR Surgical STAA | 5.69 | 207.42% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | 59.6 | 3,119.55% | ๐บ๐ธ USA |